Coldstream Capital Management Inc. Purchases 516 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Coldstream Capital Management Inc. lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 15.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,917 shares of the company’s stock after purchasing an additional 516 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Neurocrine Biosciences were worth $452,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp grew its position in Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after buying an additional 539,936 shares in the last quarter. 1832 Asset Management L.P. grew its holdings in shares of Neurocrine Biosciences by 1,370.7% during the second quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock worth $74,507,000 after purchasing an additional 504,400 shares in the last quarter. Los Angeles Capital Management LLC increased its position in shares of Neurocrine Biosciences by 639.6% in the third quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock worth $48,479,000 after purchasing an additional 363,863 shares during the last quarter. AQR Capital Management LLC raised its stake in Neurocrine Biosciences by 23.0% in the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock valued at $166,959,000 after purchasing an additional 228,444 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in Neurocrine Biosciences by 9.6% in the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock valued at $339,790,000 after purchasing an additional 216,500 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the sale, the insider now owns 15,449 shares in the company, valued at $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.30% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Trading Down 0.1 %

Shares of NASDAQ:NBIX opened at $126.70 on Friday. The company has a 50-day moving average price of $121.75 and a 200-day moving average price of $130.62. The company has a market cap of $12.83 billion, a price-to-earnings ratio of 33.97 and a beta of 0.34. Neurocrine Biosciences, Inc. has a 12 month low of $110.95 and a 12 month high of $157.98.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on NBIX shares. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. BMO Capital Markets reduced their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. HC Wainwright reiterated a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, November 1st. Finally, Jefferies Financial Group boosted their target price on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research report on Monday, August 19th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $165.18.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.